LT2822947T - Tlr7 agonisto arginino druskos - Google Patents

Tlr7 agonisto arginino druskos

Info

Publication number
LT2822947T
LT2822947T LTEP13708142.8T LT13708142T LT2822947T LT 2822947 T LT2822947 T LT 2822947T LT 13708142 T LT13708142 T LT 13708142T LT 2822947 T LT2822947 T LT 2822947T
Authority
LT
Lithuania
Prior art keywords
tlr7 agonist
arginine salts
arginine
salts
tlr7
Prior art date
Application number
LTEP13708142.8T
Other languages
English (en)
Inventor
Stephanie Kay Dodd
Siddartha JAIN
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of LT2822947T publication Critical patent/LT2822947T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
LTEP13708142.8T 2012-03-07 2013-03-07 Tlr7 agonisto arginino druskos LT2822947T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07
PCT/EP2013/054548 WO2013131985A1 (en) 2012-03-07 2013-03-07 Immunologically useful arginine salts

Publications (1)

Publication Number Publication Date
LT2822947T true LT2822947T (lt) 2016-10-10

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13708142.8T LT2822947T (lt) 2012-03-07 2013-03-07 Tlr7 agonisto arginino druskos

Country Status (18)

Country Link
US (1) US9320748B2 (lt)
EP (1) EP2822947B1 (lt)
JP (1) JP6325986B2 (lt)
CN (1) CN104203946B (lt)
AU (1) AU2013229466A1 (lt)
CA (1) CA2865759C (lt)
CY (1) CY1118091T1 (lt)
DK (1) DK2822947T3 (lt)
ES (1) ES2597755T3 (lt)
HR (1) HRP20161354T1 (lt)
HU (1) HUE030175T2 (lt)
LT (1) LT2822947T (lt)
MX (1) MX346678B (lt)
PL (1) PL2822947T3 (lt)
PT (1) PT2822947T (lt)
RU (1) RU2014140336A (lt)
SI (1) SI2822947T1 (lt)
WO (1) WO2013131985A1 (lt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
CN103313725B (zh) 2010-09-01 2016-06-29 诺华有限公司 免疫增强剂吸附不溶性金属离子
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
AU2013229432A1 (en) 2012-03-08 2014-10-16 Novartis Ag Adjuvanted formulations of booster vaccines
EA037818B1 (ru) 2014-03-26 2021-05-25 Глаксосмитклайн Байолоджикалс С.А. Мутантные стафилококковые антигены
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
WO2022192097A1 (en) * 2021-03-06 2022-09-15 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
ATE229978T1 (de) 1994-07-01 2003-01-15 Chiron Corp Helicobacter proteine und impstoffe
DK0909323T3 (da) 1996-01-04 2007-05-21 Novartis Vaccines & Diagnostic Helicobacter pylori-bakterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
DK2353608T3 (da) 2002-10-11 2020-02-10 Novartis Vaccines And Diagnostics S R L Polypeptid-vacciner til bred beskyttelse mod hypervirulente meningokok-linjer
WO2005002619A2 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
SI1858920T1 (sl) 2005-02-18 2016-07-29 Glaxosmithkline Biologicals S.A. Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
CA2608278A1 (en) 2005-05-12 2006-12-28 Guido Grandi Immunogenic compositions for chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
BRPI0818545A2 (pt) 2007-10-19 2017-07-04 Novartis Ag formulações de vacinais meningocócicas
WO2010119343A2 (en) 2009-04-14 2010-10-21 Novartis Ag Compositions for immunising against staphylococcus aureus
ES2531115T3 (es) 2009-06-01 2015-03-10 Novartis Ag Combinaciones de clados de RrgB neumocócicos
WO2010144734A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
CN102596240B (zh) 2009-08-27 2015-02-04 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
SG178954A1 (en) * 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
CN103313725B (zh) * 2010-09-01 2016-06-29 诺华有限公司 免疫增强剂吸附不溶性金属离子
US10286056B2 (en) 2011-01-27 2019-05-14 Glaxosmithkline Biologicals S.A. Adjuvant nanoemulsions with crystallisation inhibitors
CN104093418A (zh) * 2011-09-01 2014-10-08 诺华股份有限公司 金黄色葡萄球菌抗原的含佐剂制剂

Also Published As

Publication number Publication date
PL2822947T3 (pl) 2017-01-31
EP2822947A1 (en) 2015-01-14
US20150125475A1 (en) 2015-05-07
JP2015511957A (ja) 2015-04-23
HUE030175T2 (en) 2017-04-28
CA2865759C (en) 2020-07-21
WO2013131985A1 (en) 2013-09-12
CY1118091T1 (el) 2017-06-28
SI2822947T1 (sl) 2016-10-28
AU2013229466A1 (en) 2014-09-04
CN104203946B (zh) 2017-03-22
EP2822947B1 (en) 2016-08-03
CA2865759A1 (en) 2013-09-12
HRP20161354T1 (hr) 2016-12-02
MX2014010423A (es) 2014-09-22
CN104203946A (zh) 2014-12-10
MX346678B (es) 2017-03-29
DK2822947T3 (en) 2016-09-19
ES2597755T3 (es) 2017-01-20
PT2822947T (pt) 2016-09-26
RU2014140336A (ru) 2016-04-27
US9320748B2 (en) 2016-04-26
JP6325986B2 (ja) 2018-05-16

Similar Documents

Publication Publication Date Title
ZA201401884B (en) New dihydroquinoline-2-one derivatives
SI2822947T1 (sl) Argininske soli TLR7 agonista
EP2970081A4 (en) SALTS OF TREPROSTINIL
GB201304499D0 (en) Carcainium Salts
SG11201401937YA (en) New aryl-quinoline derivatives
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
ZA201308401B (en) Substituted benzamide derivatives
ZA201409327B (en) Solid forms of a pyrido-pyrimidinium inner salt
IL231269A0 (en) Preparations for the treatment of HIV
ZA201406238B (en) Crystalline form of a succinate salt
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
IL237382A0 (en) Salts of a benzothiazolone compound as beta-2 adrenergic receptor agonists
PL2760822T3 (pl) Sole desfezoterodyny
ZA201308872B (en) Use of a dinitromethane salt
GB201100332D0 (en) Monty Izofit
ZA201205358B (en) Use of a salt of bistetrazolylamine
GB201106819D0 (en) Novel salts
GB201209895D0 (en) Use of a composition
GB201219868D0 (en) Facilitating completion of a form
GB201204590D0 (en) Prodrugs of thiazolamine compounds